Bispecific antibodies have become increasingly of interest for therapeutic applications. While natural antibodies are monospecific, bispecific antibodies recognize two different epitopes either on the same or on different antigens. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including various engineering of antibody fragments in symmetric or asymmetric manner.
Superior Potency through
Low off-target binding reduces
Develop only 1 molecule and save 1/2 of investment in comparison with combination therapy
GenScript SMAB(Single-domain antibody fused to monoclonal Ab) platform naturally combine the single domain antibody and the monoclonal antibody to make a bispecific antibody in symmetric format with good biological efficacy and good developability.
SMAB Bispecific Antibody Platform is available for R&D service and co-development model.
Talk to our customer service representatives for collaboration opportunities.